ALPN News and Press, Alpine Immune Sciences Inc. From 07/09/20

The following medical companies have filed for mixed shelf offerings: More news on: Ardelyx, Inc., Vaxart, Inc., Alpine Immune Sciences, Inc., Healthcare stocks news, , Read more ...

Marathon Patent Group (NASDAQ: MARA ) -14% . More news on: Marathon Patent Group, Inc., Fuwei Films (Holdings) Co., Ltd., Urban One, Inc., Stocks on the move, , Read more ...

- ALPN-202 is a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor - Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today annou...

Evoke Pharma (NASDAQ: EVOK ) +85%  on FDA approval . More news on: Evoke Pharma, Inc., Theratechnologies Inc., Broadway Financial Corporation, Stocks on the move, , Read more ...

Broadway Financial (NASDAQ: BYFC ) +129% . More news on: Broadway Financial Corporation, Urban One, Inc., Cohen & Company Inc., Stocks on the move, Read more ...

Gainers:  Alpine Immune Sciences (NASDAQ: ALPN )  +174% . More news on: Alpine Immune Sciences, Inc., Aethlon Medical, Inc., Urban One, Inc., Stocks on the move, , Read more ...

Let me ask you a question: Why would anyone buy penny stocks ? Is it because they saw the Wolf of Wall Street or Boiler Room and want to feel a rush of adrenaline? Maybe they saw the movie Wall Street and just want to feel like Bud Fox for a day. All kidding aside though, there’s some tr...

Alpine Immune Sciences (NASDAQ: ALPN ) enters into an exclusive global option and license agreement with AbbVie (NYSE: ABBV ) for lead candidate ALPN-101. More news on: Alpine Immune Sciences, Inc., AbbVie Inc., Healthcare stocks news, Read more ...

- Alpine Immune Sciences grants AbbVie option to license worldwide rights to ALPN-101, a phase 2-ready, first-in-class dual CD28/ICOS costimulation antagonist, building on AbbVie’s commitment to developing novel therapies in Immunology - Alpine Immune Sciences to receive $60...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the AACR Virtual Annual Meeting II, taking place June...